New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2014
08:38 EDTDRTXDurata Therapeutics initiates enrollment in Phase 3b study of Dalvance
Durata Therapeutics announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvance for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
08:02 EDTDRTXActavis completes Durata Therapeutics tender offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use